Received FDA Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN)Presented data from Phase 2b ORIGIN study at ERA24 Congress…
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before…
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on…
Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA*…
Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / August…
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients- Dermata continues…
JERSEY CITY, N.J. , Aug. 7, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report…
Discover the Advanced miniDxR Customizable Lateral Flow Reader and Comprehensive CDMO and CRO Services at Booth 30 CARLSBAD, Calif, Aug.…
Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during…
Survival analyses with CNM-Au8® 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baselineCNM-Au8 treated…